Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anne Floquet1, Dominique Berton-Rigaud2, Gwenael Ferron3

  • 1Département d'oncologie médicale, Institut Bergonié, 229, cours de l'Argonne, 33076 Bordeaux, France.

Bulletin Du Cancer
|June 20, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.

Translational oncology·2026
Same author

Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network.

Gynecologic oncology·2026
Same author

Avelumab Plus Methotrexate for Gestational Trophoblastic Tumors: The TROPHAMET Phase 1/2 Nonrandomized Clinical Trial.

JAMA oncology·2026
Same author

Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial.

Oral oncology·2026
Same author

[Corrigendum to: "French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025: Management of high-grade ovarian epithelial cancer" [Bull Cancer 2026;113:191-207]].

Bulletin du cancer·2026
Same author

Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.

The New England journal of medicine·2026
This summary is machine-generated.

Ovarian cancer relapses are common and often platinum-sensitive, manageable with chemotherapy. New targeted therapies and drug reactions complicate treatment decisions, requiring personalized approaches based on patient factors and BRCA status.

Area of Science:

  • Gynecologic Oncology
  • Medical Therapeutics
  • Cancer Relapse Research

Background:

  • Ovarian cancer cure rates remain stagnant despite treatment advancements.
  • Frequent relapses characterize ovarian cancer as a chronic disease, often platinum-sensitive.
  • Current treatment strategies face challenges from new targeted therapies and drug toxicities.

Purpose of the Study:

  • To review current management strategies for platinum-sensitive ovarian cancer relapses.
  • To discuss the role of surgery and evolving medical treatments, including targeted agents.
  • To highlight factors influencing clinical decision-making in recurrent ovarian cancer.

Main Methods:

  • Review of existing literature on ovarian cancer relapse management.
  • Analysis of treatment efficacy for platinum-sensitive disease.
Keywords:
AllergieBevacizumabBévacizumabChemotherapyChimiothérapieChirurgieDrug reactionOlaparibPlatinum sensitive relapseRechute platine sensibleSurgery

Related Experiment Videos

  • Consideration of patient-specific factors and emerging therapeutic options.

    • Main Results:

    • Platinum-sensitive relapses are frequently manageable with sequential chemotherapy.
    • The precise role, patient selection, and timing of surgery require further definition.
    • New agents like bevacizumab and olaparib, alongside platinum-related allergies, complicate treatment choices.

    Conclusions:

    • Treatment decisions for recurrent ovarian cancer are complex and multifactorial.
    • Personalized medicine integrating patient profiles, prior treatments, and BRCA status is crucial.
    • Further research is needed to optimize surgical impact and navigate complex therapeutic landscapes.